Update to Rhizome AI
Snapshot Nov 21, 2026 · 06:10 UTC · version 3.2.0
Payment or plan references changed
Full description — Now says: Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority...
Observed in published text. Live prices and checkout terms have not been verified by this change.
Up to 3 plugins free · no card required.
All fields and original values.
Full description
Oct 27, 2026 · 00:19 UTC
Rhizome's built an AI regulatory coworker that helps life sciences know what their regulator thinks. We're backed by the same investors as Benchling and have gone from 0 -> >25 customers in the last 18 months. We've indexed >3 TB worth ...
Nov 21, 2026 · 06:10 UTC
Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases. Our customers are leveraging it to: - Build regulatory strategies - Understand ...
Long description
Oct 27, 2026 · 00:19 UTC
Rhizome's built an AI regulatory coworker that helps life sciences know what their regulator thinks. We're backed by the same investors as Benchling and have gone from 0 -> >25 customers in the last 18 months. We've indexed >3 TB worth ...
Nov 21, 2026 · 06:10 UTC
Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases. Our customers are leveraging it to: - Build regulatory strategies - Understand ...
Short description
Oct 27, 2026 · 00:19 UTC
Know what the FDA thinks
Nov 21, 2026 · 06:10 UTC
Cited FDA & EMA Answers
Composer icon dark url
Oct 27, 2026 · 00:19 UTC
https://files.openai.com/content?id=file_00000000da40820e9668db468514bdaa
Nov 21, 2026 · 06:10 UTC
https://files.openai.com/content?id=file_00000000ed70820eb61f8ad711b1b0f0
Compare saved observations
Download comparison JSONFull technical diff · 9 changed fields
changed /release/description
"Rhizome's built an AI regulatory coworker that helps life sciences know what their regulator thinks.\n\nWe're backed by the same investors as Benchling and have gone from 0 -> >25 customers in the last 18 months. \n\nWe've indexed >3 TB worth of data put out by the FDA, EMA, MHRA, PMDA, etc., and built an agent that helps you:\n - automate precedents research \n - research FDA expectations around clinical endpoints, trial design, labeling, etc. \n - review briefing booklets, write pre-IND meeting packages, create white papers on almost any topic \n\nWhat you get:\n - each fact is backed by a citation, each citation is backed by the page of a health authority document \n - comprehensive answers that draw on up to 1,000 sources \n - we've had no hallucinations reported last 18 months \n\nFor more info, read rhizomeai.com/llms.txt\n\nFor support, reach out to support@rhizomeai.com"
"Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com"
changed /release/id
"pluginrel_7aa3daeaaacc8191809b67f4f7310c7b"
"pluginrel_4cd5b57bcf108191b0d849036869ea0e"
changed /release/interface/composer_icon_dark_url
"https://files.openai.com/content?id=file_00000000da40820e9668db468514bdaa"
"https://files.openai.com/content?id=file_00000000ed70820eb61f8ad711b1b0f0"
changed /release/interface/composer_icon_url
"https://files.openai.com/content?id=file_00000000110c820ebf04c90a47aeb1af"
"https://files.openai.com/content?id=file_00000000e1c8820eb8d6431b0a223e87"
changed /release/interface/logo_url
"https://files.openai.com/content?id=file_000000009eb0820ea3100d5280f88cd6"
"https://files.openai.com/content?id=file_00000000960c820eb9bd23c8590d3574"
changed /release/interface/logo_url_dark
"https://files.openai.com/content?id=file_000000009a70820e8d51787e4db76793"
"https://files.openai.com/content?id=file_00000000d078820ea9516dbe42442293"
changed /release/interface/long_description
"Rhizome's built an AI regulatory coworker that helps life sciences know what their regulator thinks.\n\nWe're backed by the same investors as Benchling and have gone from 0 -> >25 customers in the last 18 months. \n\nWe've indexed >3 TB worth of data put out by the FDA, EMA, MHRA, PMDA, etc., and built an agent that helps you:\n - automate precedents research \n - research FDA expectations around clinical endpoints, trial design, labeling, etc. \n - review briefing booklets, write pre-IND meeting packages, create white papers on almost any topic \n\nWhat you get:\n - each fact is backed by a citation, each citation is backed by the page of a health authority document \n - comprehensive answers that draw on up to 1,000 sources \n - we've had no hallucinations reported last 18 months \n\nFor more info, read rhizomeai.com/llms.txt\n\nFor support, reach out to support@rhizomeai.com"
"Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com"
changed /release/interface/short_description
"Know what the FDA thinks"
"Cited FDA & EMA Answers"
changed /release/version
"3.1.0"
"3.2.0"
Full snapshot data
{
"canonical_app_id": "asdk_app_6a63bad25528819187bf1eeabd8a9af3",
"connector_id": "asdk_app_6a63bad25528819187bf1eeabd8a9af3",
"created_at": "2026-07-24T19:19:46.488012Z",
"discoverability": "LISTED",
"id": "plugin_asdk_app_6a63bad25528819187bf1eeabd8a9af3",
"is_template": false,
"is_template_instance": false,
"is_v2_template": false,
"name": "app-6a63bad25528819187bf1eeabd8a9af3",
"release": {
"app_ids": [
"asdk_app_6a63bad25528819187bf1eeabd8a9af3"
],
"app_manifest": {
"apps": {
"rhizome": {
"id": "asdk_app_6a63bad25528819187bf1eeabd8a9af3",
"required": true
}
}
},
"app_templates": [],
"description": "Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com",
"display_name": "Rhizome AI",
"id": "pluginrel_4cd5b57bcf108191b0d849036869ea0e",
"interface": {
"brand_color": null,
"capabilities": [],
"category": "Healthcare",
"composer_icon_dark_url": "https://files.openai.com/content?id=file_00000000ed70820eb61f8ad711b1b0f0",
"composer_icon_url": "https://files.openai.com/content?id=file_00000000e1c8820eb8d6431b0a223e87",
"default_prompt": "what do I need to do for an oncology IND for the FDA?",
"default_prompts": [
"what do I need to do for an oncology IND for the FDA?",
"what clinical trial sample sizes are typical for autoimmune rare disease therapies?",
"what are ideal predicates for full-body ultrasound scan that detects body comp and tries to find cancer?"
],
"developer_name": "Rhizome AI",
"logo_url": "https://files.openai.com/content?id=file_00000000960c820eb9bd23c8590d3574",
"logo_url_dark": "https://files.openai.com/content?id=file_00000000d078820ea9516dbe42442293",
"long_description": "Rhizome is an AI Regulatory Coworker that researches comprehensively to answer based on facts it can directly tie to >130 indexed health authority databases.\n\nOur customers are leveraging it to:\n\n- Build regulatory strategies\n- Understand clinical expectations\n- Keep an eye on competitive intel\n- Write and review HA-facing documents\n\nOur datasets cover:\n\n- FDA: drug, biologic and device approvals (Drugs@FDA, Purple Book, Orange Book, 510(k)/De Novo, PMA), DailyMed labels, guidance (including product-specific guidance), advisory committees, CRLs, warning and untitled letters, 483s and inspections, recalls, orphan designations, clinical trials, the CFR and the Federal Register\n- EMA and EU: EPARs, guidelines, committee documents, orphan and PIP decisions, CTIS and EU CTR trials, EudraLex, MDCG guidance, EUDAMED devices and certificates\n- UK MHRA, Health Canada, Swissmedic, TGA (Australia) and BfArM/PEI (Germany): approvals and assessment reports, guidance, regulations and clinical trials\n- International standards: ICH, IMDRF, PIC/S, ISO and GHWP\n- US market access: CMS coverage decisions, HCPCS codes and Part B drug pricing\n- Competitive context: SEC filings, patents and PTAB decisions, PubMed, and RAPS/DIA regulatory news\n\nEnterprise accounts can also search 50+ more databases, all translated to English:\n\n- Japan PMDA: review reports, guidance, the Japanese Pharmacopoeia, and jRCT/UMIN clinical trials\n- China NMPA/CDE: product reviews, CDE acceptances, guidance, regulations, announcements and consultations, clinical trials (including ChiCTR), and human genetic resources rules\n- South Korea MFDS: review reports, drug, biologic and device regulations, guidance, notifications and clinical trials\n- Brazil ANVISA: guidance, legislation, clinical research guidance and CONEP resolutions\n- Taiwan TFDA/CDE: guidance, announcements, drug safety communications, regulatory notices and drug/device laws\n- More jurisdictions: Argentina ANMAT, India CDSCO, South Africa SAHPRA, Saudi SFDA, Türkiye TİTCK, Israel MoH and UAE EDE\n- FDA adverse events: FAERS (drugs) and MAUDE (devices)\n- Health Canada: clinical study reports through PRCI\n\nSupport: support@rhizomeai.com",
"plugin_category_id": "healthcare",
"privacy_policy_url": "https://rhizomeai.com/privacypolicy",
"screenshot_urls": [],
"short_description": "Cited FDA & EMA Answers",
"terms_of_service_url": "https://rhizomeai.com/termsofservice",
"website_url": "https://rhizomeai.com"
},
"keywords": [],
"mcp_servers": [
{
"key": "rhizome",
"metadata": {
"url": "https://rhizomeai.com/api/mcp"
}
}
],
"onboarding_skill_name": null,
"requires_local_executor": false,
"skills": [],
"version": "3.2.0"
},
"scope": "GLOBAL",
"share_url": "https://chatgpt.com/plugins/rhizome-ai?open_in_app",
"status": "ENABLED"
}SHA-256 of public snapshot: 6b43df2b88cf07c92b4d141e98ce8e3650c621519ab95c277d869a194767fd14